1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Vasculitis - Pipeline Review, H1 2016

Vasculitis - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 100 pages

Vasculitis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Vasculitis - Pipeline Review, H1 2016’, provides an overview of the Vasculitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasculitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Vasculitis
- The report reviews pipeline therapeutics for Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vasculitis therapeutics and enlists all their major and minor projects
- The report assesses Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vasculitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vasculitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Vasculitis - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Vasculitis Overview 8
Therapeutics Development 9
Pipeline Products for Vasculitis - Overview 9
Pipeline Products for Vasculitis - Comparative Analysis 10
Vasculitis - Therapeutics under Development by Companies 11
Vasculitis - Therapeutics under Investigation by Universities/Institutes 12
Vasculitis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Vasculitis - Products under Development by Companies 17
Vasculitis - Products under Investigation by Universities/Institutes 18
Vasculitis - Companies Involved in Therapeutics Development 19
AnGes MG, Inc. 19
ChemoCentryx, Inc. 20
Coherus BioSciences, Inc. 21
Epirus Biopharmaceuticals, Inc. 22
F. Hoffmann-La Roche Ltd. 23
GlaxoSmithKline Plc 24
Hemostemix Ltd 25
Johnson and Johnson 26
K-Stemcell Co., Ltd. 27
Panacea Biotec Limited 28
Pfizer Inc. 29
Sandoz International GmbH 30
Stempeutics Research Private Limited 31
Teijin Pharma Limited 32
Vasculitis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
ACP-01 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
belimumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
beperminogene perplasmid - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
CCX-168 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Drug to Target Mac-1 for Vasculitis and Glomerulonephritis - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
immune globulin (human) - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
PF-1355 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
rituximab biosimilar - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
rituximab biosimilar - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
rituximab biosimilar - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
rituximab biosimilar - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
sirukumab - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Stem Cell Therapy for Thromboangiitis - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Stempeucel - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
tocilizumab - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
Vasculitis - Recent Pipeline Updates 74
Vasculitis - Dormant Projects 92
Vasculitis - Product Development Milestones 93
Featured News and Press Releases 93
Nov 25, 2015: GSK announces start of phase III study of sirukumab in Giant Cell Arteritis 93
Jun 01, 2015: Stempeutics Receives Orphan Drug Designation (ODD) in the European Union for its Novel Stem Cell Drug "Stempeucel" for the Treatment of Thromboangiitis Obliterans 93
Mar 23, 2015: Stempeutics Receives Advanced Therapy Medicinal Product (ATMP) Classification From European Medicines Agency (EMA) for its Novel Stem Cell Drug 'Stempeucel' 94
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 95
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 95
Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis 95
Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 96
May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress 96
Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis 97
Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology 98
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 99
Disclaimer 100

List of Tables
Number of Products under Development for Vasculitis, H1 2016 9
Number of Products under Development for Vasculitis - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Comparative Analysis by Unknown Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Vasculitis - Pipeline by AnGes MG, Inc., H1 2016 19
Vasculitis - Pipeline by ChemoCentryx, Inc., H1 2016 20
Vasculitis - Pipeline by Coherus BioSciences, Inc., H1 2016 21
Vasculitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 22
Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 23
Vasculitis - Pipeline by GlaxoSmithKline Plc, H1 2016 24
Vasculitis - Pipeline by Hemostemix Ltd, H1 2016 25
Vasculitis - Pipeline by Johnson and Johnson, H1 2016 26
Vasculitis - Pipeline by K-Stemcell Co., Ltd., H1 2016 27
Vasculitis - Pipeline by Panacea Biotec Limited, H1 2016 28
Vasculitis - Pipeline by Pfizer Inc., H1 2016 29
Vasculitis - Pipeline by Sandoz International GmbH, H1 2016 30
Vasculitis - Pipeline by Stempeutics Research Private Limited, H1 2016 31
Vasculitis - Pipeline by Teijin Pharma Limited, H1 2016 32
Assessment by Monotherapy Products, H1 2016 33
Number of Products by Stage and Target, H1 2016 35
Number of Products by Stage and Mechanism of Action, H1 2016 37
Number of Products by Stage and Route of Administration, H1 2016 39
Number of Products by Stage and Molecule Type, H1 2016 41
Vasculitis Therapeutics - Recent Pipeline Updates, H1 2016 74
Vasculitis - Dormant Projects, H1 2016 92

List of Figures
Number of Products under Development for Vasculitis, H1 2016 9
Number of Products under Development for Vasculitis - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 33
Number of Products by Targets, H1 2016 34
Number of Products by Stage and Targets, H1 2016 34
Number of Products by Mechanism of Actions, H1 2016 36
Number of Products by Stage and Mechanism of Actions, H1 2016 36
Number of Products by Routes of Administration, H1 2016 38
Number of Products by Stage and Routes of Administration, H1 2016 38
Number of Products by Molecule Types, H1 2016 40
Number of Products by Stage and Molecule Types, H1 2016 40

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Pipeline Review, H2 2016

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Pipeline ...

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline Review, H2 2016

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.